FALCON trial of fulvestrant for advanced breast cancer
The Phase III FALCON trial compared fulvestrant to anastrozole for hormone receptor-positive advanced breast cancer.
Prof. Matthew Ellis from the Baylor College of Medicine presented the trial and talked to us about its design, the results and implications. In the interview, he explains that the study was designed to address the question if there is an optimal first-line endocrine therapy for patients with hormone receptor-positive advanced breast cancer who had not been treated with a hormonal agent before. The primary endpoint of the study was progression-free survival (PFS); Prof. Ellis highlights that “patients on fulvestrant stayed on the drug in response approximately three months longer than patients on anastrozole” (16.6 months vs 13.8 months). Prof. Ellis further points out that the results were statistically significant but the question is, if they are clinically significant. He explains that these kinds of differences as observed in this trial, have driven changes in clinical practice before as in the case of tamoxifen and aromatase inhibitors.
If you would like to discover how we can leverage our network of relationships and understanding of the oncology landscape and stakeholders, to shape content and amplify messages across relevant audiences, channels and communities please contact either Stephen Dunn or Charlie Grieve on 020 7291 5070, we’d be delighted to hear from you.
We talked to Dr Bettina Ryll of Melanoma Patient Network Europe about changes in melanoma treatment and how the added complexity of new treatments has changed how patients need to be informed. Brandcast Health